Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“Major achievement by Immutep Limited Biotech today as we may be on the verge of achieving successful novel mechanism combination therapy with Keytruda (Pembrolizumab) in the 1st line metastatic non-small cell lung cancer (mNSCLC).
TACTI-004 (Two ACTive Immunotherapies) (KEYNOTE-F91) Phase III study (NCT06726265) reached enrollment of 170 patients, which triggers futility analysis, and results are anticipated in 1Q2026. TACTI-004 is testing eftilagimod alfa (efti), a first-in-class MHC Class II agonist, in combination with Merck Keytruda (Pembrolizumab) and chemotherapy as first-line therapy for patients with mNSCLC with no EGFR, ALK, or ROS1 genomic tumor aberrations.
Based on earlier efti studies (TACTI-002 and INSIGHT-003), there is a lot of room for optimism and hopefully great news for mNSCLC patients where novel combinations with Keytruda so far have had limited success.”
More posts featuring Tanja Obradovic on OncoDaily.